SCHEMBL2642060

SCHEMBL2642060

Cc1ccc(Nc2ncnc3ccc(Sc4nc[nH]n4)nc23)nc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.34
NPC1 O15118 5/20 0.34
POLB P06746 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
EGFR P00533 6/20 0.33
MEN1 O00255 5/20 0.33
KMT2A Q03164 5/20 0.33
GAA P10253 5/20 0.33
ALDH1A1 P00352 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
PDE5A O76074 1/20 0.33
SYK P43405 1/20 0.33
MAPT P10636 4/20 0.32
KDM4E B2RXH2 3/20 0.32
SLC2A1 P11166 1/20 0.32
MKNK2 Q9HBH9 2/20 0.32
DYRK3 O43781 1/20 0.32
ABL1 P00519 1/20 0.32
CDK1 P06493 1/20 0.32
CSF1R P07333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642284 0.88 MKNK2 (0.41) EGFRMKNK2
SCHEMBL2659577 0.80 RAB9A (0.35) RAB9ANPC1POLBSMN1; SMN2EGFR
SCHEMBL2659755 0.68 MKNK2 (0.43) EGFRMKNK2
SCHEMBL2658886 0.68 GCK (0.33) EGFRMKNK2
SCHEMBL2642273 0.67 GCK (0.34) EGFRSYKMKNK2
SCHEMBL2642347 0.67 EGFR (0.33) EGFRSYKMKNK2ADRA2AADRA2C
SCHEMBL2662750 0.66 ADRA2A (0.35) EGFRMKNK2ADRA2AADRA2BADRA2C
SCHEMBL2642396 0.62 GCK (0.32)
SCHEMBL2890024 0.62 HTT (0.50) RAB9ANPC1POLBSMN1; SMN2EGFR
SCHEMBL2642193 0.61 GCK (0.40) EGFRLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US claimed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP claimed
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK RAB9A 1818/4885NPC1 3557/4885POLB 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.